• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Production of factor VIII by genetic techniques].

作者信息

Neutzling O

机构信息

Baxter Biotech, Hyland Division, Unterschleissheim, BRD.

出版信息

Beitr Infusionsther. 1993;31:38-43.

PMID:7693262
Abstract

The human factor VIII gene and the human von Willebrand factor gene have been isolated, and were transfected into a mammalian cell line (Chinese Hamster Ovary Cells = CHO Cells). The resulting factor VIII producing cell line was thoroughly characterized. No differences were found in the recombinant factor VIII compared to plasma-derived factor VIII. For factor VIII production the cells are grown in serum-free defined medium, the recombinant factor VIII is purified by immunoaffinity chromatography plus two subsequent ion exchange steps. The absence of human raw materials for production, and a proven titer reduction of > 10(7) in the purification process significantly minimize the risk of virus transmission by the recombinant factor VIII product. Clinical studies both with previously treated and untreated patients have proven the good hemostatic efficacy and virus safety of the recombinant factor VIII. The inhibitor incidence in previously untreated patients is within the expected range for this patient group.

摘要

相似文献

1
[Production of factor VIII by genetic techniques].
Beitr Infusionsther. 1993;31:38-43.
2
Biotechnology and the plasma fractionation industry--the impact of advances in the production of coagulation factor VIII.生物技术与血浆分馏行业——凝血因子VIII生产进展的影响
Australas Biotechnol. 1993 Jan-Feb;3(1):16-20.
3
Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.血友病患者从使用中国仓鼠卵巢细胞生产的重组因子VIII改为使用幼仓鼠肾细胞生产的重组因子VIII后,抑制剂形成的风险较低。
Thromb Haemost. 2007 Dec;98(6):1188-92.
4
Expression of biologically active human factor VIII using a baculovirus vector.使用杆状病毒载体表达具有生物活性的人凝血因子VIII
Biochem Biophys Res Commun. 1993 Jan 29;190(2):536-43. doi: 10.1006/bbrc.1993.1081.
5
[Factor VIII preparation produced by recombinant DNA-technology is approved in Norway].挪威批准了通过重组DNA技术生产的凝血因子VIII制剂。
Tidsskr Nor Laegeforen. 1995 Jun 10;115(15):1849-51.
6
Establishment of a cell line expressing recombinant factor VII and its subsequent conversion to active form FVIIa through hepsin by genetic engineering method.通过基因工程方法建立表达重组因子VII的细胞系,并通过组织蛋白酶将其转化为活性形式的FVIIa。
Vox Sang. 2009 May;96(4):309-15. doi: 10.1111/j.1423-0410.2008.01158.x. Epub 2009 Jan 19.
7
Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.血浆源性单克隆纯化因子VIII浓缩物10年随访期间的安全性和有效性。
Haemophilia. 2007 Nov;13(6):697-700. doi: 10.1111/j.1365-2516.2007.01554.x. Epub 2007 Sep 18.
8
Viral safety of recombinant factor IX.重组凝血因子IX的病毒安全性
Semin Hematol. 1998 Apr;35(2 Suppl 2):22-7.
9
Second generation, B-domain deleted recombinant factor VIII.
Thromb Haemost. 1997 Jul;78(1):256-60.
10
Development and validation of an affinity chromatography step using a peptide ligand for cGMP production of factor VIII.使用肽配体的亲和色谱步骤用于cGMP生产因子VIII的方法开发与验证。
Biotechnol Bioeng. 2004 Aug 5;87(3):400-12. doi: 10.1002/bit.20124.